Oxaliplatin in practice

British Journal of Cancer

Volumn 77, Issue SUPPL. 4, 1998, Pages 4-7

  Misset, J L ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Colorectal cancer; Ovarian cancer; Oxaliplatin; Reversible peripheral sensory neuropathy

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; FLUOROURACIL; OXALIPLATIN; PYRIMIDINE ANTAGONIST;

ADVANCED CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; GASTROINTESTINAL TOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE IV; COLORECTAL NEOPLASMS; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 0031809686     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.428     Document Type: Article

References (14)

1. Alvarez et al (1994) Proc Am Assoc Cancer Res 35: 439 A, 2616
2. Caussanel J-P, Lévi F, Brienza S et al (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050
3. Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303
4. de Gramont A, Vignoud J, Tournigand C et al (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219
5. Lévi F, Misset JL, Brienza S et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69: 893-900
6. Massari C, Brienza S, Rotarski M et al (1994) Oxaliplatin (L-OHP, Transplatin®) comparative pharmacokinetics (Pk) and tolerance in normal (NRF) and impaired renal function (IRF) patients. Ann Oncol 5 (suppl. 5): 126 (abstract 217)
7. Massari et al. (1996) Am Assoc Cancer Res 37 (abstract 2516)
8. Mathé G, Kidani Y, Triana K et al (1986) A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (I-OHP). Biomed Pharmacother 40: 372-376
9. Missel JL et al (1991) In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Howell SB (ed.), Plenum Press: New York
10. Misset JL, Chollet P, Vennin P, Laplaige P, Lucas V, Frobert JL, Castera D, Fabbro M, Langlois D, Dupont-André G, Otero G and Fandi A (1997) Multicentric Phase II-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (c) in the treatment of advanced ovarian cancer (AOC): toxicity efficacy results. Proc Am Soc Clin Oncol 16 (abstract 1266)
11. Pendyala L and Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 53: 5970-5976
12. Raymond E, Taamma A, Cvitkovic E et al (1998) Preclinical and clinical studies of oxaliplatin. Ann Oncol (in press)
13. Soulie P, Bonsmaine A, Garrino C et al (1997) Oxaliplatin/cisplatin (L-OHP/ CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33: 1400-1406
14. Soulie P et al (1996) In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Pinedo (ed.), Plenum Press: New York